Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Oct 31, 2026

Completed

Study on [14C] Levornidazole Disodium Phosphate for Injection in Healthy Chinese Adult Male Subjects

Oct 31, 2026

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Levornidazole Disodium Phosphate for Injection in Subjects With Hepatic Impairment: An Open-Label, Parallel, Single-Dose Study

Earlier

Jun 30, 2026TrialAn Open-Label, Parallel, Single-Dose Study to Assess the Pharmacokinetics and Safety of Levornidazole Disodium Phosphate for Injection in Subjects With Varying Degrees of Renal Impairment

Jun 26, 2026TrialA Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Nalbuphine Versus Morphine for the Treatment of Postoperative Analgesia

Dec 20, 2023TrialPharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy Chinese Volunteers

May 10, 2023TrialA Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)